on Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Protagonist Therapeutics to Participate in BTIG Virtual Biotechnology Conference 2024
NEWARK, CA / ACCESSWIRE / July 22, 2024 - Protagonist Therapeutics, Inc. (NASDAQ:PTGX) announced that Dr. Dinesh V. Patel, President and CEO, will join the BTIG Virtual Biotechnology Conference. The event will feature a fireside chat and one-on-one meetings.
The conference is scheduled for August 5-6, 2024. Dr. Patel’s participation in the fireside chat will occur on August 6, from 2:00 to 2:35 P.M. EDT. Interested parties can contact their BTIG representatives to arrange meetings with the Protagonist team.
Protagonist Therapeutics is advancing peptide-based new chemical entities, rusfertide and JNJ-2113, in Phase 3 clinical development. Rusfertide, targeting polycythemia vera, is in a global Phase 3 VERIFY study in collaboration with Takeda. More details are available on their website.
R. P.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Protagonist Therapeutics, Inc. news